ARCHIVES

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

This article is from The Cancer Letter archive.

Vol. 33 No. 18 | May 11, 2007

Download PDF Visit The Full Archive

Related Articles

Afinitor Significantly Reduced Tumor Size In TSC-Related Renal Angiomyolipomas

January 25, 2013

“We Will Move Forward With Bold Expectations,” NCI Director Says

October 2, 1998

Consensus Conference Planned On Adjuvant Chemotherapy For Breast Cancer

March 22, 1985

FDA Approves Xeloda For Breast Cancer After Failure Of Anthracycline Treatment.

September 28, 2001

In Brief: City of Hope launches Hematologic Malignancies and Stem Cell Transplantation Institute

October 31, 2014

Tacoma Hospital Finds Cancer DRGs Are Profitable

February 17, 1984